You are here

Organized Lipid Matrix: Fatty Acids and Choline in CF

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44DK060302-02A1
Agency Tracking Number: DK060302
Amount: $6,196,530.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Timeline
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
AVANTI POLAR LIPIDS, INC. 700 INDUSTRIAL PARK DRIVE
Alabaster, AL 35007
United States
DUNS: N/A
HUBZone Owned: Unavailable
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 WALTER SHAW
 (205) 663-2494
 WALTSHAW@AVANTILIPIDS.COM
Business Contact
Phone: (800) 227-0651
Email: WALTSHAW@AVANTILIPIDS.COM
Research Institution
N/A
Abstract

Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased levels of linoleic acid and an increased triene/tetraene ratio, and an associated choline deficiency. As a key membrane phospholipid, choline is required for methyl metabolism, cholinergic neurotransmission, transmembrane signaling, lipid cholesterol transport and metabolism. Choline deficiency is associated with liver disease, apoptosis, steatosis, as well as brain and visual development abnormalities. In a previous randomized control trial, supplementation with LYM-X-SORB(TM), an organized lipid matrix containing lysophosphatidylcholine (LPC) monoglycerides, and triglycerides, has been shown to improve fatty acid status and vitamin E and retinol binding protein levels over a 12-month period and to improve both growth and pulmonary function status over 18 months in subjects with CF. We propose to conduct a randomized placebo-controlled double-blinded study to evaluate the effectiveness of the next generation LYM-X-SORB(TM) with improved palatability and mixing characteristics, on fatty acid and choline status of 78 children, ages 6.0 to 17.9 years, with CF and PI. We propose that essential fatty acid status (linoleic acid levels, triene/tetraene ratio) and choline status (phosphadytlcholine/ phosphatidytlethanolamine (PC/PE) ratio) will be normalized after 12 mos of supplementation with LYM-X-SORB(TM) in subjects receiving LYM-X-SORB(TM) (n=39) compared to those receiving placebo (n=39). We will also explore whether LYM-X-SORB(TM) supplementation will improve fat soluble vitamin status, bile composition, incidence of fatty liver, inflammatory cytokines, resting energy expenditure and respiratory quotient over 12 mos and improve pulmonary function, growth status, body composition and overall health status over 18 mos. Subjects will be recruited from five Cystic Fibrosis Centers and have four major protocol visits to CHOP (baseline, 3, 12, and 18 mos), and one visit at their home Center (6 mos). Our objective is to determine if LYM-X-SORB(TM) can be used as an acceptable, effective, supplement to correct the metabolic and physiological abnormalities associated with fat malabsorption in subjects with CF, the most commonly inherited genetic disease in Caucasians.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government